To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity
Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vacc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/5/805 |
| _version_ | 1797535516988538880 |
|---|---|
| author | Felicia Schlotthauer Joey McGregor Heidi E Drummer |
| author_facet | Felicia Schlotthauer Joey McGregor Heidi E Drummer |
| author_sort | Felicia Schlotthauer |
| collection | DOAJ |
| description | Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vaccines focused largely on generating T cell immunity, attention is now aimed at vaccines that generate humoral immunity, either alone or in combination with T cell-based vaccines. High-resolution structures of hepatitis C viral glycoproteins and their interaction with monoclonal antibodies isolated from both cleared and chronically infected people, together with advances in vaccine technologies, provide new avenues for vaccine development. |
| first_indexed | 2024-03-10T11:45:52Z |
| format | Article |
| id | doaj.art-05c2224d4bb142338bc23d72e251a2ff |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T11:45:52Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-05c2224d4bb142338bc23d72e251a2ff2023-11-21T18:04:08ZengMDPI AGViruses1999-49152021-04-0113580510.3390/v13050805To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral ImmunityFelicia Schlotthauer0Joey McGregor1Heidi E Drummer2Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, AustraliaViral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, AustraliaViral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, AustraliaDirect-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vaccines focused largely on generating T cell immunity, attention is now aimed at vaccines that generate humoral immunity, either alone or in combination with T cell-based vaccines. High-resolution structures of hepatitis C viral glycoproteins and their interaction with monoclonal antibodies isolated from both cleared and chronically infected people, together with advances in vaccine technologies, provide new avenues for vaccine development.https://www.mdpi.com/1999-4915/13/5/805glycoprotein E2vaccine developmenthumoral immunity |
| spellingShingle | Felicia Schlotthauer Joey McGregor Heidi E Drummer To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity Viruses glycoprotein E2 vaccine development humoral immunity |
| title | To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity |
| title_full | To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity |
| title_fullStr | To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity |
| title_full_unstemmed | To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity |
| title_short | To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity |
| title_sort | to include or occlude rational engineering of hcv vaccines for humoral immunity |
| topic | glycoprotein E2 vaccine development humoral immunity |
| url | https://www.mdpi.com/1999-4915/13/5/805 |
| work_keys_str_mv | AT feliciaschlotthauer toincludeoroccluderationalengineeringofhcvvaccinesforhumoralimmunity AT joeymcgregor toincludeoroccluderationalengineeringofhcvvaccinesforhumoralimmunity AT heidiedrummer toincludeoroccluderationalengineeringofhcvvaccinesforhumoralimmunity |